Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

Inclusion criteria

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2;
• Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count≥1.5×109/L, Platelet count≥100×109/L, Hemoglobin≥80g/L, Serum bilirubin≤24umol/L, Alanine aminotransferase and aspartate aminotransferase ≤ 60×IU/L, Serum creatinine≤110 umol/L;
• No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of contraception ;
• Be in a condition to receive a surgery/procedure;
• No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer;
• No previous systemic chemotherapy for treating colon cancer;
• No other chemotherapy at the same time;
• Expected lifetime longer than three months;
• Be willing and able to understand the study and to provide written informed consent.

Exclusion criteria

• End-stage cachexia patients;
• Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate CapeOX chemotherapy;
• Metastatic carcinoma;
• Moderate or above anemia caused by serious local tumor bleeding;
• Incomplete or complete intestinal obstruction;
• Known to be allergic to oxaliplatin or capecitabine;
• Active hepatitis, severe coagulation disorder patients;
• Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures;
• Known to have deficient dihydropyrimidine dehydrogenase (DPD)；
• Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric history；severe infection; active disseminated intravascular coagulation;
• Unable or unwilling to abide by the study plan.